Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601066 | 1.00 | MAPT (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3597750 | 0.89 | KDM4E (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3597753 | 0.89 | KDM4E (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL13316663 | 0.89 | KDM4E (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL13316631 | 0.89 | KDM4E (0.36) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3599878 | 0.88 | MAPT (0.36) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3599874 | 0.88 | MAPT (0.36) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3607891 | 0.87 | KDM4E (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3607886 | 0.87 | KDM4E (0.37) | MAPTKDM4EKMT2AMEN1ATM | |
| SCHEMBL3603051 | 0.87 | KDM4E (0.39) | MAPTKDM4EKMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| EP-1686983-B1 | USE OF PENTADIENOIC ACID DERIVATES FOR TREATEMENT OF HYPERURICEMIA | MERCK PATENT GMBH (DE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | XDH, URB2, ALOX12 | MAPT 3339/4885KDM4E 4711/4885KMT2A 4388/4885 |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | MAPT 3339/4885KDM4E 4711/4885KMT2A 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.